Literature DB >> 11945107

Interactions between psychotropics, anaesthetics and electroconvulsive therapy: implications for drug choice and patient management.

Mohamed Naguib1, Robert Koorn.   

Abstract

Despite many predictions that electroconvulsive therapy (ECT) would be replaced by pharmacotherapy, ECT has remained an invaluable adjunct in the management of severe psychiatric disease. Both pharmacotherapy and ECT continue to be used extensively, and will frequently be administered concurrently. The majority of patients requiring ECT will need anaesthesia; therefore, interactions could conceivably occur between the psychotropic drugs, ECT and the anaesthetic agents utilised. In managing an anaesthetic for ECT the effects of the anaesthetic agents and other medications on seizure intensity are important determinants influencing outcome. With regard to the antidepressants, tricyclic antidepressants (TCAs) and ECT can be combined safely and beneficially. More care is required when ECT is administered in the setting of a monoamine oxidase inhibitor (MAOI), especially the older irreversible varieties and in patients recently placed on MAOI therapy. Of the anticonvulsants and mood stabilisers, lithium and ECT given concurrently add significant risk of delirium and/or organic syndromes developing. Possible concerns with valproate, carbamazepine, lamotrigine, gabapentin and topiramate are that they may inhibit seizure activity. Additionally, carbamazepine may prolong the action of suxamethonium (succinylcholine). The combination of antipsychotics and ECT is well tolerated, and may in fact be beneficial. As regards the anxiolytics, benzodiazepines have anticonvulsant properties that might interfere with the therapeutic efficacy of ECT. CNS stimulants on the other hand may prolong seizures as well as produce dysrhythmias and elevate blood pressure. Calcium channel antagonists should be used with great care to avoid significant cardiovascular depression. The anaesthesiologist should therefore remain vigilant at all times, as untoward responses during ECT might occur suddenly due to interactions between psychotropics, anaesthetic agents and/or ECT.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11945107     DOI: 10.2165/00023210-200216040-00003

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  192 in total

1.  Fluoxetine and ECT.

Authors:  Charles H. Kellner; Renee M. Bruno
Journal:  Convuls Ther       Date:  1989

Review 2.  Antidepressant-induced lipidosis with special reference to tricyclic compounds.

Authors:  Z Xia; G Ying; A L Hansson; H Karlsson; Y Xie; A Bergstrand; J W DePierre; L Nässberger
Journal:  Prog Neurobiol       Date:  2000-04       Impact factor: 11.685

3.  Cardiac responses to imipramine and pancuronium during anesthesia with halothane or enflurane.

Authors:  R P Edwards; R D Miller; M F Roizen; J Ham; W L Way; C R Lake; L Roderick
Journal:  Anesthesiology       Date:  1979-05       Impact factor: 7.892

4.  Comparison of two esmolol bolus doses on the haemodynamic response and seizure duration during electroconvulsive therapy.

Authors:  A L Kovac; H Goto; M P Pardo; K Arakawa
Journal:  Can J Anaesth       Date:  1991-03       Impact factor: 5.063

5.  Does Fluoxetine Prolong Electrically Induced Seizures?

Authors:  Rolando Gutierrez-Esteinou; Harrison G. Pope
Journal:  Convuls Ther       Date:  1989

6.  Imipramine's selective suppression of an L-type calcium channel in neurons of murine dorsal root ganglia involves G proteins.

Authors:  J J Choi; G J Huang; E Shafik; W H Wu; J J McArdle
Journal:  J Pharmacol Exp Ther       Date:  1992-10       Impact factor: 4.030

7.  Comparative effects of carbamazepine and carbamazepine-10,11-epoxide on hepatic cytochromes P450 in the rat.

Authors:  S K Panesar; S M Bandiera; F S Abbott
Journal:  Drug Metab Dispos       Date:  1996-06       Impact factor: 3.922

8.  Decreased sensitivity to metocurine during long-term phenytoin therapy may be attributable to protein binding and acetylcholine receptor changes.

Authors:  C S Kim; F J Arnold; M S Itani; J A Martyn
Journal:  Anesthesiology       Date:  1992-09       Impact factor: 7.892

9.  Midazolam-thiopental anesthetic interaction in patients.

Authors:  M Tverskoy; G Fleyshman; E L Bradley; I Kissin
Journal:  Anesth Analg       Date:  1988-04       Impact factor: 5.108

10.  Propranolol in schizophrenia. II. Clinical and biochemical aspects of combining propranolol with chlorpromazine.

Authors:  M Peet; D N Middlemiss; R A Yates
Journal:  Br J Psychiatry       Date:  1981-08       Impact factor: 9.319

View more
  12 in total

Review 1.  [Anaesthesiological aspects of electroconvulsive therapy].

Authors:  U Grundmann; M Oest
Journal:  Anaesthesist       Date:  2007-03       Impact factor: 1.041

2.  ECT-induced Mania.

Authors:  Jae Lee; Laura Arcand; Puneet Narang; Steven Lippmann
Journal:  Innov Clin Neurosci       Date:  2014 Nov-Dec

Review 3.  Guide to anaesthetic selection for electroconvulsive therapy.

Authors:  Klaus J Wagner; Oliver Möllenberg; Michael Rentrop; Christian Werner; Eberhard F Kochs
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

4.  A comparison of propofol and thiopentone for electroconvulsive therapy.

Authors:  Alok Kumar; Devendra Kumar Sharma; Raghunandan Mani
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2012-07

5.  Chronic subdural hematoma following electro convulsive therapy.

Authors:  Debasish Saha; Bikash Bisui; Rajarshi Guha Thakurta; Sumanta Ghoshmaulik; Om Prakash Singh
Journal:  Indian J Psychol Med       Date:  2012-04

Review 6.  Electroconvulsive therapy and its different indications.

Authors:  Thomas C Baghai; Hans-Jürgen Möller
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

7.  Atrioventricular dissociation after electroconvulsive therapy.

Authors:  Siegfried William Yu; Srikanth Vallurupalli; Jennifer Arnoldi; Richard Holloway
Journal:  Cardiol Res Pract       Date:  2011-09-15       Impact factor: 1.866

8.  Effects of stimulus parameters on motor seizure duration in electroconvulsive therapy.

Authors:  Sung Woo Joo; Yeon Ho Joo; Chang Yoon Kim; Jung Sun Lee
Journal:  Neuropsychiatr Dis Treat       Date:  2017-05-29       Impact factor: 2.570

9.  Medication management during electroconvulsant therapy.

Authors:  Monica Zolezzi
Journal:  Neuropsychiatr Dis Treat       Date:  2016-04-19       Impact factor: 2.570

10.  Sudden cardiac death after modified electroconvulsive therapy.

Authors:  Zhihui Wang; Jiyu Wang
Journal:  Shanghai Arch Psychiatry       Date:  2015-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.